Q-omics provides the consensus-scored TCAF1 profile across patient tissues and cancer cell-line models. TCAF1 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, TCAF1 is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, TCAF1 RNA expression shows 20,524 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, HNSC, and UVM as cancer lineages where TCAF1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TCAF1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TCAF1 survival associations across molecular data types. TCAF1 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (2) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TCAF1 RNA expression–survival associations across cancer types. High TCAF1 expression shows unfavorable associations in LUSC and LUAD, but favorable associations in KIRC, ACC, UCS and OV. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for TCAF1 RNA expression.
This table summarizes TCAF1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for TCAF1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TCAF1 shows lower tumor expression in THCA and UCEC and higher tumor expression in HNSC, KIRP, KIRC and BLCA. The HNSC box plot shows higher TCAF1 RNA expression in tumor versus normal tissue (log2 FC = +0.736, t-test p < 0.001).
This table shows molecular features associated with TCAF1 in patient tissues and cancer cell lines. In patient samples, TCAF1 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, TCAF1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BLOOD_Leukemia.
